UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041299
Receipt number R000047161
Scientific Title Attempt to raise the pH of gastric juice during gastric ESD
Date of disclosure of the study information 2020/08/04
Last modified on 2023/08/05 13:59:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Attempt to raise the pH of gastric juice during gastric ESD

Acronym

Attempt to raise the pH of gastric juice during gastric ESD

Scientific Title

Attempt to raise the pH of gastric juice during gastric ESD

Scientific Title:Acronym

Attempt to raise the pH of gastric juice during gastric ESD

Region

Japan


Condition

Condition

gastric csncer

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Tests related to gastric acid secretion, such as basal secretion (BAO), followed by a post-stimulant maximal secretion test (MAO) and a pH monitor, are performed, but they are somewhat invasive. In recent years, with the increase in the use of endoscopy, the proportion of gastric cancer cases detected at an early stage has increased and the number of endoscopic submucosal dissection procedures has also increased. On the other hand, however, with the aging population, bleeding after endoscopic treatment, especially endoscopic submucosal dissection, is a growing concern. It is well known that neither platelet aggregation nor plasma coagulation occurs at a gastric juice pH below 5.3. Conventional gastric acid secretion inhibitors (PPIs) require several days to reach a high pH level, while the recently introduced bonoprazan is said to raise the pH level within a few hours after administration. However, the recent introduction of Bonoprazan has been reported to raise the pH of gastric juice a few hours after endoscopy. In this study, we examined intragastric pH, post-endoscopic gastric bleeding, post-endoscopic ulcer healing tendency, and ulcer size by collecting gastric fluid samples at the time of endoscopic treatment after oral Bonoprazan was administered from the day before endoscopic treatment.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

On the day of ESD, gastric juice is collected and measured for pH before the endoscopic procedure, and an upper gastrointestinal endoscopy is performed the day after the completion of ESD and at 2 months to confirm the size and healing of the ulcer after endoscopic treatment.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The day before gastric ESD, vonoprazan 20 mg/day is taken after dinner and ESD is performed.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

90 years-old >=

Gender

Male and Female

Key inclusion criteria

Patients diagnosed with early-stage gastric cancer or gastric adenoma by upper gastrointestinal endoscopy, who are indicated for endoscopic treatment and who are not taking vonoprazan or H2A by oral medication are eligible.

Key exclusion criteria

Exclude people who are already taking PPIs

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Masashi
Middle name
Last name Yoshida

Organization

International University of Health and Welfare Hospital

Division name

Department of Surgery

Zip code

329-2763

Address

537-3, Iguchi, Nasushiobara, Tochigi 329-2763, Japan

TEL

0287-39-3060

Email

masashi@iuhw.ac.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Suto

Organization

International University of Health and Welfare Hospital

Division name

Department of Gastroenterology

Zip code

329-2763

Address

537-3, Iguchi, Nasushiobara, Tochigi 329-2763, Japan

TEL

0287-39-3060

Homepage URL


Email

daisuto@iuhw.ac.jp


Sponsor or person

Institute

International University of Health and Welfare Hospital

Institute

Department

Personal name



Funding Source

Organization

International University of Health and Welfare Hospital

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

International University of Health and Welfare Hospital

Address

537-3, Iguchi, Nasushiobara, Tochigi 329-2763, Japan

Tel

0287-39-3060

Email

daisuto@iuhw.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 08 Month 04 Day


Related information

URL releasing protocol

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578543/pdf/main.pdf

Publication of results

Published


Result

URL related to results and publications

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578543/pdf/main.pdf

Number of participants that the trial has enrolled

18

Results

There were 14 cases of post-ESD bleeding in patients treated with proton-pump inhibitors (PPIs), including oozing during second-look endoscopy compared to only 1 case of bleeding with vonoprazan administration. Vonoprazan was also associated with better post-ESD ulcer healing than PPIs. Gastric pH during ESD after vonoprazan administration on the night before gastric ESD was 6.96 in all 11 patients.

Results date posted

2023 Year 08 Month 05 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results

2020 Year 10 Month 07 Day

Baseline Characteristics

Patient undergoing endoscopic submucosal dissection for early gastric cancer but not taking gastric acid secretion inhibitors

Participant flow

Patient undergoing endoscopic submucosal dissection for early gastric cancer but not taking gastric acid secretion inhibitors

Adverse events

None

Outcome measures

Measurement of gastric juice PH

Plan to share IPD

None

IPD sharing Plan description

None


Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 06 Month 19 Day

Date of IRB

2019 Year 06 Month 19 Day

Anticipated trial start date

2019 Year 06 Month 19 Day

Last follow-up date

2023 Year 08 Month 05 Day

Date of closure to data entry

2023 Year 08 Month 05 Day

Date trial data considered complete

2023 Year 08 Month 05 Day

Date analysis concluded

2023 Year 08 Month 05 Day


Other

Other related information



Management information

Registered date

2020 Year 08 Month 03 Day

Last modified on

2023 Year 08 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047161


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name